Cost Benefits of an Outpatient Diagnostic Pathway for Low-Risk Transient Ischemic Attack: A Narrative Review

Transient ischemic attack (TIA) affects at least 240,000 people in the United States each year, and most of them are still admitted to the hospital for a workup that takes one to two days. The main reason for admission is rarely treatment. It is diagnostic convenience: inpatient echocardiography, cardiac telemetry, and specialist consultation. Over the past two decades, rapid-access TIA clinics and emergency department (ED) observation protocols have shown that the same evaluation can be completed without a hospital bed, with 90-day stroke rates of 1% to 2% that compare favorably with predicted rates of 6% to 10%. This review examines the financial case for an ED-based discharge pathway in which low-risk patients (ABCD2 score <4, no infarct on imaging, no severe vascular stenosis) complete brain and vessel imaging and laboratory studies in the ED, then obtain echocardiography, ambulatory cardiac monitoring, and structured follow-up as outpatients within days of discharge. Published comparisons consistently show cost reductions of 40% to 80% per patient when hospitalization is replaced with urgent outpatient evaluation, with no measurable loss of safety. A decision analysis found that hospitalization costs $5,573 more per patient than urgent clinic evaluation while adding only 0.00026 quality-adjusted life-years. Using a national average hospital expense of $3,297 per inpatient day, a program discharging 100 low-risk patients annually can be expected to free roughly $330,000 to $660,000 in hospital production costs and 100 to 200 bed-days each year. The pathway also reduces out-of-pocket costs for insured patients, who avoid inpatient deductibles and coinsurance. Cost savings, bed capacity, and patient preference align in the same direction, and the remaining barriers are organizational rather than clinical.